Krebs H B, Girtanner R E, Nordqvist S R, Mineau I, Helmkamp B F, Averette H E
Cancer. 1980 Nov 15;46(10):2159-61. doi: 10.1002/1097-0142(19801115)46:10<2159::aid-cncr2820461009>3.0.co;2-m.
A combination of bleomycin and mitomycin-C, reported as extraordinarily effective in a previous clinical trial, was used to treat 20 patients with advanced cervical cancer. Seven partial remissions (35%) and one complete remission (5%) were observed. Six of the partial remissions were of short duration (less than four months); the only patient with complete remission was still alive without evidence of disease ten months after initiation of chemotherapy. Nonresponders had a mean survival time of 6.6 months and responders 8.0 months. The treatment results confirm some efficacy of the drug regimen, although in our hands it did not live up to the high expectations raised by others.
博来霉素与丝裂霉素-C联合使用,在前一项临床试验中据报道疗效显著,此次用于治疗20例晚期宫颈癌患者。观察到7例部分缓解(35%)和1例完全缓解(5%)。6例部分缓解持续时间较短(少于4个月);唯一完全缓解的患者在化疗开始10个月后仍存活,且无疾病迹象。未缓解者的平均生存时间为6.6个月,缓解者为8.0个月。治疗结果证实了该药物方案的一定疗效,尽管在我们手中它并未达到其他人所提出的高期望。